Masaru Takeshita and his team at Keio University School of Medicine in Tokyo have identified a vicious cycle at the heart of Sjögren's disease—one that could finally explain why this autoimmune disorder stubbornly persists in millions of patients worldwide, and how to stop it.
Sjögren's disease attacks the body's own exocrine glands, the salivary and lacrimal glands that keep your mouth and eyes moist. Patients experience relentless dry mouth and dry eyes, and the disease can progress to affect the skin, lungs, kidneys, and nerves. Yet despite its prevalence, no cure exists. Doctors typically prescribe broad immunosuppressive drugs that blunt the entire immune system rather than addressing root causes—a blunt instrument that leaves patients vulnerable to infections and other complications.
A defining feature of Sjögren's disease is the presence of anti-Ro60 autoantibodies, antibodies that mistakenly target the body's own Ro60 protein. Scientists have long studied B cells, the immune cells that produce these antibodies, but the role of CD4+ T cells—the coordinators of immune responses that activate other immune cells—remained a mystery. Takeshita's team suspected these two cell types work together to fuel chronic autoimmunity, but pinning down exactly how has eluded researchers until now.
The breakthrough came through meticulous detective work. Using single-cell RNA sequencing and T-cell receptor analysis, the researchers examined immune cells extracted from the salivary glands of patients with Sjögren's disease. They identified more than 200 distinct T-cell receptors and tested whether each could recognize fragments of the Ro60 protein. From this vast library, they isolated 13 TCRs that specifically recognized Ro60-derived peptides—the first disease-associated CD4+ T cells linked to the target protein.
What they discovered next reveals the trap the immune system creates. The Ro60-reactive T cells belong to specialized subsets of CD4+ T cells known to stimulate antibody-producing B cells. Those B cells then produce anti-Ro60 antibodies that bind to Ro60 proteins released from damaged cells, forming immune complexes. Antigen-presenting cells engulf these complexes and display the Ro60 peptides to CD4+ T cells, which become activated and prompt even more antibody production. The loop closes. The disease perpetuates itself.
"Simply put, this process forms a self-reinforcing loop, sustaining autoimmune responses and contributing to chronic disease," Takeshita explained in the research published in Science Advances.
Perhaps most significantly, this mechanism held true across both Japanese and Caucasian patients, suggesting it represents a universal feature of anti-Ro60-positive Sjögren's disease independent of genetic background. That consistency hints at a genuine therapeutic target, not a quirk of a single population.
The implications are profound. If researchers can interrupt this specific loop—rather than carpet-bombing the entire immune system—Sjögren's patients might finally have access to therapies that eliminate harmful autoimmune responses while preserving protective immune functions. For millions living with relentless dry eyes and mouth, and the risk of progressive organ damage, that prospect offers genuine hope.